- Bestsellers
- Alcoholism
- COVID-19
- Allergy
- Anti Fungal
- Alzheimers
- Anti Viral
- Anti-Depressants
- Anti-Inflammatory
- Antibacterial
- Antiparasitic
- Antibiotics
- Arthritis
- Asthma
- Birth Control
- Blood Pressure
- Cancer
- Cardiovascular
- Cholesterol
- Diabetes
- Diuretics
- Erectile Dysfunction
- Eye Drop
- Gastro Health
- General Health
- Hair Loss
- Hepatitis C Virus (HCV)
- HIV
- Hormones
- Men's ED Packs
- Men's Health
- Mental Illness
- Motion Sickness
- Muscle Relaxant
- Pain Relief
- Parkinson’s Disease
- Veterinary Medicines
- Quit Smoking
- Vitamins
- Skin Care
- Sleeping Aids
- Weight Loss
- Women's Health
Generic Imiquimod
Imiquimod cream 5% is a topical immune response modifier indicated for the treatment of clinically typical, non‑hyperkeratotic, non‑hypertrophic actinic keratoses on the face or scalp in immunocompetent adults, the treatment of superficial basal cell carcinoma when surgical removal is less appropriate, and the treatment of external genital and perianal warts (condyloma acuminata) in patients aged 12 years and older. Imiquimod does not have direct antiviral or cytotoxic activity; instead, it stimulates the local innate and cell‑mediated immune responses by inducing cytokines, including interferon‑alpha, tumor necrosis factor‑alpha, and interleukins, which help eliminate virus‑infected cells and precancerous or malignant keratinocytes.
Usual adult dose: For actinic keratoses, apply Imiquimod 5% cream 2 times per week (e.g., Monday and Thursday) to the entire affected area before bedtime and leave on for approximately 8 hours, after which the cream should be washed off with mild soap and water. The treatment course is 16 weeks. For superficial basal cell carcinoma, apply 5 times per week (e.g., Monday through Friday) for a 6‑week course, leaving the cream on for approximately 8 hours before washing off. For external genital and perianal warts, apply 3 times per week (e.g., Monday, Wednesday, Friday) until wart clearance or for a maximum of 16 weeks; the cream is left on for 6 to 10 hours and then removed. A thin layer is spread over the clean, dry area and gently massaged until absorbed. If a severe local skin reaction occurs, a temporary rest period of several days may be necessary; treatment can then resume when the reaction subsides.
Dosage form: Topical cream: 5% (each 250 mg sachet contains 12.5 mg of imiquimod). Available in boxes of 12 or 24 single‑use sachets, and as a pump bottle containing 5.25 g of cream.
Onset of action: A visible inflammatory response (erythema, edema, vesicles, erosion) typically appears within 2 to 4 weeks of initiation and is an expected indicator of immune activation. For actinic keratoses, clearance is assessed after the 16‑week treatment period; for superficial basal cell carcinoma, clinical and histological clearance is determined approximately 12 weeks after completing the 6‑week course. Genital warts often begin to regress after several weeks of use.
Duration of action: Treatment is delivered over a finite course lasting 6 to 16 weeks depending on the indication. The immune‑mediated clearance continues beyond the application period, and the induced immune memory may provide a reduced risk of recurrence of treated lesions.
Alcohol recommendation: No systemic interaction exists between topical imiquimod and the consumption of alcoholic beverages. However, patients should avoid applying alcohol‑based products, astringents, or other potential irritants to the treatment area because they can intensify local skin reactions and discomfort.
Most common side effects: Local skin reactions at the application site occur in nearly all patients and include erythema, edema, induration, vesicles, erosion/ulceration, scabbing/crusting, flaking/scaling, itching, and burning. These reactions are a normal part of the immune response and often correlate with treatment effectiveness. Flu‑like symptoms such as fatigue, fever, myalgia, and headache may also occur. Because imiquimod can cause photosensitivity, patients should minimize or avoid exposure to sunlight and artificial ultraviolet light and use a broad‑spectrum sunscreen. The cream should not be applied to unhealed wounds or sunburned skin. Treatment must be temporarily discontinued if severe local discomfort or systemic symptoms develop, and the need for dose adjustment should be discussed with a healthcare professional. Imiquimod is not recommended for use during pregnancy (FDA Category C) unless the potential benefit justifies the potential risk.
Would you like to try Imiquimod cream 5% without a prescription?
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Package delivery insurance
+ Next orders 10% discount
+ Package delivery insurance
+ Next orders 10% discount
+ Package delivery insurance
+ Next orders 10% discount
+ Package delivery insurance
+ Next orders 10% discount
